The European Commission has granted a conditional marketing authorisation for a Covid-19 vaccine developed by Moderna Inc based on clinical data showing an efficacy rate of 94.1%. The vaccine, COVID-19 Vaccine Moderna, is to be administered to people from 18 years of age. It is the second Covid-19 vaccine to be approved by the EU following a recommendation by the European Medicines Agency. The first was a vaccine developed by BioNTech SE and Pfizer Inc. Both vaccines are based on messenger RNA (mRNA) technology.
